Please login to the form below

Not currently logged in
Email:
Password:

oral anticoagulant

This page shows the latest oral anticoagulant news and features for those working in and with pharma, biotech and healthcare.

UPDATED: BMS completes $13.1bn acquisition of MyoKardia

UPDATED: BMS completes $13.1bn acquisition of MyoKardia

This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... However, BMS is facing competition from generic rivals of Eliquis – in December 2019, the FDA approved

Latest news

More from news
Approximately 0 fully matching, plus 78 partially matching documents found.

Latest Intelligence

  • Digital disruption in market access Digital disruption in market access

    publication of the first direct oral anticoagulant technology appraisal, we are not yet there.

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Warfarin, an oral vitamin K antagonist (VKA) approved in the early 1950s, has ruled the anticoagulant market for nearly six decades. ... Delays and withdrawals. Eli Lilly was developing a once-daily, piperazine class, oral anticoagulant called LY 517717

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...